Ginkgo Bioworks Holdings (DNA) Cash from Financing Activities (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Cash from Financing Activities of -$19000.0 for Q1 2026, down 100.23% on a QoQ basis from $8.1 million in Q4 2025, and up 90.82% year-over-year from -$9957.0 in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$19000.0 for Q1 2026.
- Quarterly Cash from Financing Activities rose 90.82% year-over-year to -$19000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.0 million (up 1731.52% YoY) and the FY2025 annual result came in at $17.8 million, up 1122.14% from the prior year.
- Cash from Financing Activities was -$19000.0 for Q1 2026 at Ginkgo Bioworks Holdings, down from $8.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $97.8 million in Q4 2022 and bottomed at -$1.4 million in Q2 2023.
- A 5-year average of $6.4 million and a median of -$315000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 175.29% — and 2025, when it surged 4110.84%.
- Ginkgo Bioworks Holdings' Cash from Financing Activities stood at $97.8 million in 2022, then plunged by 100.65% to -$632000.0 in 2023, then soared by 67.88% to -$203000.0 in 2024, then jumped by 4110.84% to $8.1 million in 2025, then tumbled by 100.23% to -$19000.0 in 2026.
- Business Quant data shows DNA's Cash from Financing Activities at -$19000.0 in Q1 2026, $8.1 million in Q4 2025, and $9.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | -19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19,000.00 |
| Mar 31, 2026 | -19,000.00 |
| Dec 31, 2025 | 8.14 Mn |
| Dec 31, 2025 | 8.14 Mn |
| Sep 30, 2025 | 9.94 Mn |
| Sep 30, 2025 | 9.94 Mn |
| Jun 30, 2025 | -98,000.00 |
| Jun 30, 2025 | -98,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Dec 31, 2024 | -203,000.00 |
| Dec 31, 2024 | -203,000.00 |
| Sep 30, 2024 | -465,000.00 |
| Sep 30, 2024 | -465,000.00 |
| Jun 30, 2024 | -226,000.00 |
| Jun 30, 2024 | -226,000.00 |
| Mar 31, 2024 | -845,000.00 |
| Mar 31, 2024 | -845,000.00 |
| Dec 31, 2023 | -632,000.00 |
| Dec 31, 2023 | -632,000.00 |